Cargando…
Individualized approach to elexacaftor/tezacaftor/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series
The prevalence of mental health disorders is high among people with Cystic Fibrosis. The psychological symptoms in CF are associated with poor adherence, worse treatment outcomes, and greater health utilization/cost. Mental health and neurocognitive Adverse Events (AEs) have been reported with all a...
Autores principales: | Ibrahim, Hisham, Danish, Hammad, Morrissey, David, Deasy, Kevin F., McCarthy, Mairead, Dorgan, James, Fleming, Claire, Howlett, Ciara, Twohig, Sarah, Vagg, Tamara, Murphy, Desmond M., Maher, Michael, Plant, Barry J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172465/ https://www.ncbi.nlm.nih.gov/pubmed/37180712 http://dx.doi.org/10.3389/fphar.2023.1156621 |
Ejemplares similares
-
Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021) -
Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety
in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022) -
Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
por: Tümmler, Burkhard
Publicado: (2023) -
Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation
por: Roder, Lauren, et al.
Publicado: (2022) -
ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2020)